EW
Edwards Lifesciences Corporation
September 16, 2026 · intraday
- Rarity
- 1.36
- Peak move
- +4.43%
- Float cap
- —
Edwards Lifesciences Corporation develops and sells medical technologies for structural heart disease. Its portfolio includes transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical heart valves and repair products. These therapies are used by cardiac surgeons and interventional cardiologists to treat patients with aortic, mitral, tricuspid, and pulmonic valve disease and other advanced cardiovascular conditions.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
11 events · 0 from SEC or newswire · 0 timed with the moveinsider_saleEdwards Lifesciences VP Daniel J. Lippis sold 619 shares at an average price of $87.51 on Sept 11 under a pre-arranged Rule 10b5-1 plan, leaving him 40,034 shares.
institutional_flowBank of America Corp DE disclosed a new position of 6,692,424 Edwards Lifesciences shares valued at approximately $605.4 million, or 1.16% of the company, per its latest 13F filing for the second quarter.
- Key event
executive_remarkAt the Deutsche Bank 2026 Healthcare Summit on Sept 16, Edwards Lifesciences CEO Bernard Zovighian and CFO Doretta Mistras discussed five therapy areas (TAVR AS, PASCAL, EVOQUE, SAPIEN M3, surgical), a mitral/tricuspid opportunity exceeding the earlier $2B-by-2030 target, 100-200 of ~250 eligible US cardiac surgery centers potentially opening TAVR programs, capacity gains of 20%-40% for simple TAVR cases under a new CMS policy, and guidance that TMTT revenue should reach ~$250M in 2026, up ~40%, with long-term sales growth targeted at ~10% a year.
- Key event
buybackCFO Doretta said Edwards Lifesciences has repurchased more than $500 million of its own shares year-to-date, describing buybacks as opportunistic rather than programmatic.
- Key event
regulatory_approvalBeijing Customs said the EVOQUE transcatheter tricuspid valve replacement system cleared Beijing Tianzhu Comprehensive Bonded Zone in four batches across four models and will be transferred to Fuwai Hospital for clinical use in China.
insider_saleEdwards Lifesciences officer Markowitz Wayne sold 568 shares on Sept 14, 2026, per a Form 4 beneficial-ownership filing disclosed that day, one of three insider transactions reported.
large_option_expiryTraders acquired 2,518 Edwards Lifesciences call options on Monday, Sept 14, 2026, a 93% increase over the average daily call volume of 1,303 contracts.
institutional_flowCorient Private Wealth LP increased its Edwards Lifesciences stake by 1,028.9% in the second quarter, adding 227,947 shares to hold 250,101 shares worth approximately $22.6 million.
analyst_ratingCanaccord reiterated a Hold rating and $85.00 price target on Edwards Lifesciences following the CMS TAVR Medicare coverage decision.
regulatory_approvalCMS finalized its updated National Coverage Determination for TAVR on Sept. 10, 2026, classifying TAVR as reasonable and necessary, expanding Medicare coverage to asymptomatic severe aortic stenosis patients, removing the coverage-with-evidence-development requirement and facility volume thresholds, allowing single-physician evaluation and remote second opinions, and adding workflow flexibility; Edwards welcomed the decision and estimates 100-200 of ~250 eligible US cardiac surgery centers could open TAVR programs.
analyst_ratingCiti analyst Joanne Wuensch maintained a Buy rating on Edwards Lifesciences and set a $110.00 price target, following CMS's finalized TAVR national coverage decision.